Slowly progressing type 1 diabetes: persistence of islet cell autoantibodies is related to glibenclamide treatment. - Cabrera-Rode E; Perich P; Diaz-Horta O; Tiberti C; Molina G; Arranz C; Martin JM; Licea M; De Leiva AD; Puig-Domingo M; Dimario U (Autoimmunity, 2002)